Skip to main content

8 Result(s)

within Mark Temper Remove this filter

and

  1. No Access

    Article

    Multiplexed, single-molecule, epigenetic analysis of plasma-isolated nucleosomes for cancer diagnostics

    The analysis of cell-free DNA (cfDNA) in plasma provides information on pathological processes in the body. Blood cfDNA is in the form of nucleosomes, which maintain their tissue- and cancer-specific epigeneti...

    Vadim Fedyuk, Nir Erez, Noa Furth, Olga Beresh… in Nature Biotechnology (2023)

  2. Article

    Author Correction: ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin

    A Correction to this paper has been published: https://doi.org/10.1038/s41587-021-00831-9.

    Ronen Sadeh, Israa Sharkia, Gavriel Fialkoff, Ayelet Rahat… in Nature Biotechnology (2021)

    Download PDF (642 KB) View Article

  3. Article

    Author Correction: ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin

    A Correction to this paper has been published: https://doi.org/10.1038/s41587-021-00853-3.

    Ronen Sadeh, Israa Sharkia, Gavriel Fialkoff, Ayelet Rahat… in Nature Biotechnology (2021)

    Download PDF (642 KB) View Article

  4. No Access

    Article

    ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin

    Cell-free DNA (cfDNA) in human plasma provides access to molecular information about the pathological processes in the organs or tumors from which it originates. These DNA fragments are derived from fragmented...

    Ronen Sadeh, Israa Sharkia, Gavriel Fialkoff, Ayelet Rahat… in Nature Biotechnology (2021)

  5. Article

    Open Access

    Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience

    Precision treatment of cancer uses biomarker-driven therapy to individualize and optimize patient care.

    Ofer Purim, Alexander Beny, Moshe Inbar, Katerina Shulman… in Targeted Oncology (2018)

    Download PDF (1102 KB) View Article

  6. No Access

    Article

    An observational cohort study of bevacizumab and chemotherapy in metastatic colorectal cancer patients: safety and efficacy with analysis by age group

    Bevacizumab improves survival when added to chemotherapy in metastatic colorectal cancer (mCRC). We assessed the safety and efficacy of bevacizumab in mCRC patients ≥70 years old (YO) vs. those <70 YO. mCRC pa...

    Esther Tahover, Ayala Hubert, Mark Temper, Azzam Salah, Tamar Peretz… in Targeted Oncology (2015)

  7. No Access

    Article

    Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients

    Bevacizumab treatment is associated with an increased risk of hypertension (HTN), a potential marker for effectiveness. We aimed to assess whether grades 2–3 HTN during bevacizumab treatment was associated wit...

    Esther Tahover, Beatrice Uziely, Azzam Salah, Mark Temper, Tamar Peretz… in Medical Oncology (2012)

  8. No Access

    Article

    Absence of founder BRCA1 and BRCA2 mutations in coetaneous malignant melanoma patients of Ashkenazi origin

    Introduction Several epidemiologic studies have provided suggestive evidence of a link between coetaneous malignant melanoma (CMM) and breast cancer. The Breast Cancer Linkage Consortium (BCLC) reported approxima...

    Luna Kadouri, Mark Temper, Tal Grenader, Dvorah Abeliovich… in Familial Cancer (2009)